CN110804634B - 酶催化法制备2,4-二氨基丁酸的工艺 - Google Patents

酶催化法制备2,4-二氨基丁酸的工艺 Download PDF

Info

Publication number
CN110804634B
CN110804634B CN201911229933.7A CN201911229933A CN110804634B CN 110804634 B CN110804634 B CN 110804634B CN 201911229933 A CN201911229933 A CN 201911229933A CN 110804634 B CN110804634 B CN 110804634B
Authority
CN
China
Prior art keywords
ala
leu
gly
val
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201911229933.7A
Other languages
English (en)
Other versions
CN110804634A (zh
Inventor
于铁妹
樊卫
林立峰
何平
潘俊锋
刘建
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gansu Ruidilin Biological Co ltd
Shenzhen Readline Biotechnology Co ltd
Original Assignee
Shenzhen Readline Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Readline Biotechnology Co ltd filed Critical Shenzhen Readline Biotechnology Co ltd
Priority to CN201911229933.7A priority Critical patent/CN110804634B/zh
Publication of CN110804634A publication Critical patent/CN110804634A/zh
Application granted granted Critical
Publication of CN110804634B publication Critical patent/CN110804634B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00Preparation of nitrogen-containing organic compounds
    • C12P13/04Alpha- or beta- amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38Separation; Purification; Stabilisation; Use of additives
    • C07C227/40Separation; Purification

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

本发明涉及生化技术领域,公开了突酶催化法制备2,4‑二氨基丁酸的工艺。本发明以L‑天冬氨酸为起始,通过一系列的酶促反应生成天冬氨酸‑4‑磷酸、天冬氨酸半醛中间体,最后转化成目标产物2,4‑二氨基丁酸;整个反应体系还可增加四种辅酶再生体系,降低ATP、NADPH、NADH以及丙氨酸的用量,有效推动该反应至高转化率。本发明反应体系多种酶催化反应相互不干扰,反应操作简便,其最终产品转化率高,如采用固定化酶方式则可进一步提高其工业应用可行性。

Description

酶催化法制备2,4-二氨基丁酸的工艺
技术领域
本发明涉及生化技术领域,具体涉及酶催化法制备2,4-二氨基丁酸的工艺。
背景技术
2,4-二氨基丁酸是一种自然界中存在的一种非天然氨基酸,它是类似赖氨酸、鸟氨酸的二氨基氨基酸;其分子式为C4H10N2O2,分子量为118,CAS No:305-62-4。2,4-二氨基丁酸大量分布在植物,花、酵母及部分细菌中,它虽然不是蛋白质的基本组成,但其广泛参与多种天然多肽抗菌素的生物合成,如圈杆菌素(polypeptin)、柯密菌素(Comirin)、多黏菌素(Polymyxin)等等。2,4-二氨基丁酸同时也具有较高的工业应用价值,譬如它是生产蛇毒肽的基本原料(蛇毒肽是毒蛇蛇腺分泌的一种物质,具有镇痛、止血、抑制血栓形成及抗肿瘤等药理作用;蛇毒肽现被广泛应用在医美行业,是一种祛皱抗皱有效成份),因而开发一种更为简便的、能批量生产2,4-二氨基丁酸的方法以降低其成本变得比较重要。
2,4-二氨基丁酸常用的制备方法有分离法及化学合成法。虽然自然界2,4-二氨基丁酸分布较广,但由于其丰度低、分子量小、水溶性大等特征导致其分离纯化非常困难;市面上大部分销售的2,4-二氨基丁酸是通过化学合成的方法制备的,比较经典的制备工艺利用L-天冬氨酸在叠氮化钠、浓硫酸及氯仿条件下直接转化成2,4-二氨基丁酸(最高收率能到90%,G.I.Tesser and J.W.Van Nispen,“NOTE ON THE PREPARATION Of L-2,4-DIAMINOBUTYRIC ACID,Synthetic communication,1971,1,285-287),该工艺延续至今,然而由于该反应涉及多个有毒、易爆化学品,因而其规模化生产的安全风险非常大。在当今提倡安全、绿色生产的大环境下,寻找一种廉价的、环保的2,4-二氨基丁酸生产方法变得比较迫切。
发明内容
有鉴于此,本发明的目的在于提供一种酶催化法制备2,4-二氨基丁酸的工艺,使得所述工艺转化收率高、目标产物浓度高、产物杂质残留低,纯化工艺简单。
为实现上述目的,本发明提供如下技术方案:
一种酶催化法制备2,4-二氨基丁酸的工艺,反应原料L-天冬氨酸、ATP或其盐、磷酸吡哆醛、丙氨酸、NADPH或其盐在pH值6.0-9.0的反应介质中,与天冬氨酸激酶ASK、天冬氨酸半醛氧化酶ASADH及转氨酶AMT进行酶催化反应,生成2,4-二氨基丁酸。
本发明针对目前的化学合成法的诸多缺陷,利用酶促反应技术提供了另外一种从L-天冬氨酸开始合成2,4-二氨基丁酸的工艺。L-天冬氨酸激酶(ASK,EC 2.7.2.4),它能磷酸化L-天冬氨酸成L-天冬氨酸-4-磷酸;而天冬氨酸半醛氧化酶(ASADH,EC 1.2.1.11)则能在还原型烟酰胺腺嘌呤二核苷酸磷酸NADPH存在下将L-天冬氨酸-4-磷酸转化成L-天冬氨酸半醛;最后非专一性
Figure BDA0002303254320000022
-转氨酶(AMT,EC 2.6.1.-)在磷酸吡哆醛(PLP)存在条件下将丙氨酸上的氨基转移到L-天冬氨酸半醛,生成2,4-二氨基丁酸。
其中,所述各酶以表达各酶的宿主细胞、各酶的酶液或各酶的固定化酶形式参与酶催化反应。
在本发明具体实施方式中,所述表达各酶的宿主细胞为含有表达各酶的载体的大肠杆菌;其具体的制备过程如下:
以提取的大肠杆菌(Escherichia coliK12)、斯氏假单胞菌(Pseudomonasstutzeri)染色体、ATCC购买的耻垢分枝杆菌(Mycobacterium smegmatis mc2 155,ATCC700084)、伯克霍尔德菌(Burkholderia multivorans,ATCC 17616)等染色体为模板,用各酶引物PCR扩增出ASK、ASADH、AMT、PPK、PDH、ADH以及FDH基因片段,然后进行相应酶切、酶连接到载体质粒上;
通过基因测序验证正确的质粒进而转入E.coli BL21(DE3)菌株中,于LB培养液中进行培养,然后IPTG条件下诱导表达,收集各酶的湿细胞。
更为具体地,所述载体质粒为市售的pET28a质粒,各酶扩增引物见表1:
表1
Figure BDA0002303254320000021
Figure BDA0002303254320000031
通过基因测序验证正确的质粒进而转入E.coli BL21(DE3)菌株中,在37℃、5ml含50uM卡那霉素(Kanamycin)的LB培养液中进行小量培养,当细胞生长至OD 0.5-0.8加入0.4mM异丙基-β-D-硫代吡喃半乳糖苷(IPTG),37℃诱导蛋白表达4小时,最后收集细胞、冻融法进行细胞破碎、高速离心,收集到的上清液再利用十二烷基磺酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)确认蛋白表达。蛋白表达正确的菌株逐级培养至5升发酵罐,在0.5mM IPTG条件下37℃诱导表达6小时,收集各酶的湿细胞。LB培养基构成为:1%胰蛋白胨、0.5%酵母粉,1%NaCl,1%磷酸氢二钾,1%磷酸氢二钾以及5%的甘油。
在本发明具体实施方式中,所述天冬氨酸激酶ASK、天冬氨酸半醛氧化酶ASADH及转氨酶AMT的序列依次如SEQ ID NO.1-3所示。
在本发明具体实施方式中,所述各酶的酶液为从表达各酶的宿主细胞中提取的酶液;方法为将所收集的湿细胞经过高压破碎、高速离心收集含粗蛋白的上清液,即为含酶的酶液,也可以对上清液进一步纯化。
作为优选,本发明还包括2,4-二氨基丁酸的纯化步骤:
过色谱柱除盐,然后阴离子交换树酯除去溶液中磷酸化合物,最后收集的2,4-二氨基丁酸粗品经冻干后重结晶。其中,所述色谱柱为G25色谱柱,去离子水做洗脱液;所述阴离子交换树酯为D201阴离子交换树酯;所述重结晶采用乙醇水溶液,乙醇和水的体积比优选为3:1。
作为优选,所述反应介质为三羟甲基氨基甲烷盐酸(Tris.HCl),更优选为100mMpH 8.0的三羟甲基氨基甲烷盐酸(Tris.HCl)。同时,在酶催化反应过程中维持体系pH值为6-9,优选为6.5-8.5。
本发明反应中由于要用到辅酶三磷酸腺苷(ATP)及NADPH,通过引入ATP再生酶(PPK,EC 2.7.4.1)与多聚磷酸,NADP再生酶(PDH,EC 1.20.11.1)与亚磷酸就可以实现其循环利用,大大降低其使用量。转氨基酶(AMT)反应为平衡反应,通过在体系中引入甲酸铵、丙氨酸脱氢酶(ADH,EC 1.4.1.1)以及甲酸脱氢酶(FDH,EC 1.17.1.9),在催化剂量的还原型辅酶烟酰胺腺嘌呤二核苷酸(NADH)存在下可以循环再生丙氨酸,这不仅可以降低丙氨酸的用量,使其只需要催化剂量即可,还可以有效推动该转氨反应至高转化率。与此同时,通过将本发明所涉及的酶一次性或多次性进行固定化应用则可进一步提高其稳定性及规模化生产的可操作性。
因此,本发明所述工艺还包括向反应原料中添加多聚磷酸、亚磷酸或其盐、甲酸铵、氯化钾、氯化镁(氯化钾和氯化镁参与ATP再生酶PPK的反应)、NADH或其盐,以及添加ATP再生酶PPK、NADP再生酶PDH、丙氨酸脱氢酶ADH以及甲酸脱氢酶FDH进行酶催化反应;本发明整体的反应原理示意图见图1。
在本发明中,所述ATP的盐为ATP钠盐,如三磷酸腺苷二钠盐;所述NADPH盐为NADPH钠盐,如还原型烟酰胺腺嘌呤二核苷酸磷酸NADPH单钠盐;所述NADH盐为NADH钠盐,如还原型辅酶烟酰胺腺嘌呤二核苷酸NADH二钠盐;所述亚磷酸盐为亚磷酸钠盐,如亚磷酸钠;各物质的盐均可提供ATP、NADPH、NADH以及亚磷酸。
在本发明具体实施方式中,所述ATP再生酶PPK、NADP再生酶PDH、丙氨酸脱氢酶ADH以及甲酸脱氢酶FDH的序列依次如SEQ ID NO.4-7所示。
按照本发明工艺制备2,4-二氨基丁酸,纯品最终收率可达70%以上,最高可达到87%,接近化学合成方法的收率,但相比经典的化学合成方法更加安全、环保和低成本。
由以上技术方案可知,本发明以L-天冬氨酸为起始,通过一系列的酶促反应生成天冬氨酸-4-磷酸、天冬氨酸半醛中间体,最后转化成目标产物2,4-二氨基丁酸;整个反应体系还可增加四种辅酶再生体系,降低ATP、NADPH、NADH以及丙氨酸的用量,有效推动该反应至高转化率。本发明反应体系多种酶催化反应相互不干扰,反应操作简便,其最终产品转化率高,如采用固定化酶方式则可进一步提高其工业应用可行性。
附图说明
图1所示为本发明反应原理示意图。
具体实施方式
本发明公开了酶催化法制备2,4-二氨基丁酸的工艺,本领域技术人员可以借鉴本文内容,适当改进工艺参数实现。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明。本发明工艺已经通过较佳实施例进行了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文工艺进行改动或适当变更与组合,来实现和应用本发明技术。
本发明所述工艺的步骤旨在清楚的描述核心的反应路线,并不限制整个反应采用一步法还是多步法进行。
本发明所采用的各酶可以根据序列进行人工合成,也可按照本发明提供的方法通过质粒载体搭载各酶表达基因,借助宿主细胞诱导表达。
在进行固定化时,可参照本领域常规的固定化酶制备方式,在本发明具体实施方式中,本发明利用LX-1000EP环氧树脂(西安蓝晓公司)按照ASK、ASADH、AMT、PPK、PDH、ADH、FDH粗酶以活力比1:2.2:4.5:2.5:4.0:6.0:5.0进行一次性混合固定,其固定方法如下:2000-4000U混合酶溶解在1L25mM pH 8.0的磷酸钾溶液中,随后加入25-65mM苯氧乙酸以及300-500克LX-1000EP环氧树脂至缓冲液,室温搅拌4-8小时后过滤出固定化酶,最后用清水以及25mM pH 8.0磷酸缓冲液各洗涤三次后低温保存待用;固定化混合酶分别具有液体酶的30-70%的活性。
依照本发明工艺的反应路线,各反应物质的用量可以根据实际情况调整,为了最大效率化,本发明提供了如下各反应物质的摩尔比:
L-天冬氨酸、多聚磷酸、ATP、丙氨酸、亚磷酸、氯化镁、氯化钾、甲酸铵、NADPH、ASK、ASADH、AMT、NADH、PPK、PDH、ADH、FDH、PLP=1:(1.1):(0.02):(0.02):(1.1):2:5:(1.1):(0.02):(0.0002):(0.0003):(0.0005):(0.02):(0.001):(0.0005):(0.001):(0.0015):(0.00005);
在本发明具体实施方式中,各酶以湿细胞方式参与酶催化反应时,按照12克:24克:48克:24克:48克:60克:48克的比例加入过量表达ASK、ASADH、AMT、PPK、PDH、ADH以及FDH酶的湿细胞;
各酶以含酶液方式加参与酶催化反应时,ASK、ASADH、AMT、PPK、PDH、ADH以及FDH酶液以1:2:4:2:4:6:4体积比混合后一次性加入;
各酶以固定化酶方式加参与酶催化反应时,参照上述固定化方法中的比例。
下面结合实施例,进一步阐述本发明。
实施例1:湿细胞一锅法催化生产2,4-二氨基丁酸
在1L 100mM pH 8.0的三羟甲基氨基甲烷盐酸(Tris.HCl)溶液中先后加入6.65克L-天冬氨酸(50mM),1.1克三磷酸腺苷二钠盐ATP(2mM)、5.7克多聚磷酸(Sigma,25聚,55mM单磷酸)、0.9克氯化镁(10mM)、0.75克氯化钾(10mM)、还原型烟酰胺腺嘌呤二核苷酸磷酸NADPH单钠盐0.76克(1.0mM)、还原型辅酶烟酰胺腺嘌呤二核苷酸NADH二钠盐0.71克(1.0mM)、亚磷酸钠6.8克(55mM)、甲酸氨3.8克(60mM)、丙氨酸89毫克(1mM)、磷酸吡哆醛0.7毫克(0.0025mM),待pH值调节到8.0后,以12克:24克:48克:24克:48克:60克:48克的比例加入过量表达ASK、ASADH、AMT、PPK、PDH、ADH以及FDH酶的湿细胞。反应过程中通过加入低浓度的HCl及NaOH水溶液维持反应体系pH 6.0-9.0之间,30℃轻微搅拌6小时后直接离心(8000rpm,12min)除去含酶细胞,反应清液通过G25色谱柱除盐(去离子水做洗脱液),D201阴离子交换树酯(晶祥化工)除去溶液中含磷酸化合物(各种腺苷,NAD及NADP),最后收集的2,4-二氨基丁酸粗品经冻干后用乙醇及水重结晶(3:1v/v)得白色固体4.9克纯2,4-二氨基丁酸钠(最终收率70%)。
纯化后2,4-二氨基丁酸在600M Varian D2O溶液中核磁谱图结果数据:
1H-NMR:2.04(m,2.0H),2.65(t,2.0H),3.49(t,1.0H);
13C-NMR:174.7(COOH),52.9(CH),37.5(CH2),28.9(CH2).
实施例2:液体酶一锅法催化生产2,4-二氨基丁酸
收集的含天冬氨酸激酶ASK、天冬氨酸半醛氧化酶ASADH、转氨基酶AMT、ATP再生酶PPK、NADP再生酶PDH、丙氨酸脱氢酶ADH以及甲酸脱氢酶FDH细胞混合在20倍体积的25mMTris pH 8.0的缓冲液(缓冲液A)里,然后经过高压破碎、高速离心(16000rpm,45min)收集含粗蛋白的上清液,该酶粗液直接进行下一步反应制备2,4-二氨基丁酸。
与实施例1类似,在1L 100mM pH 8.0的三羟甲基氨基甲烷盐酸(Tris.HCl)溶液中先后加入26.6克L-天冬氨酸(200mM),1.1克三磷酸腺苷二钠盐ATP(2mM)、22.8克多聚磷酸(Sigma,25聚,220mM单磷酸)、0.9克氯化镁(10mM)、0.75克氯化钾(10mM)、还原型烟酰胺腺嘌呤二核苷酸磷酸NADPH单钠盐1.5克(2.0mM)、还原型辅酶烟酰胺腺嘌呤二核苷酸NADH二钠盐1.4克(2.0mM)、亚磷酸钠27克(220mM)、甲酸氨15.5克(240mM)、丙氨酸0.35克(4mM)、磷酸吡哆醛2.8毫克(0.01mM),待pH值调节到8.0后,ASK、ASADH、AMT、PPK、PDH、ADH以及FDH酶液以1:2:4:2:4:6:4混合后一次性加入,通过酸碱调节维持反应液pH值在6.5-8.5,30℃轻微搅拌4小时后直接加酸调节反应液pH值到1.5。充分搅拌、离心除去酶沉淀;调节反应清液至pH7.5,然后依据上述方法通过G25色谱柱除盐,D201阴离子交换树酯除含磷酸化合物,最后冻干结晶得24.3克白色固体(收率87%)。
纯化后2,4-二氨基丁酸在600M Varian D2O溶液中核磁谱图结果数据:
1H-NMR:2.04(m,2.0H),2.65(t,2.0H),3.49(t,1.0H);
13C-NMR:174.7(COOH),52.9(CH),37.5(CH2),28.9(CH2).
实施例3:固定化酶一锅法催化生产2,4-二氨基丁酸
收集的含天冬氨酸激酶ASK、天冬氨酸半醛氧化酶ASADH、转氨基酶AMT、ATP再生酶PPK、NADP再生酶PDH、丙氨酸脱氢酶ADH以及甲酸脱氢酶FDH细胞混合在20倍体积的25mMTris pH 8.0的缓冲液(缓冲液A)里,然后经过高压破碎、高速离心(16000rpm,45min)收集含粗蛋白的上清液,往溶液中逐量加入硫酸铵固体直至其洗出(35%-55%,w/v硫酸铵/缓冲液)。该酶固体通过离心(10000rpm,12min)收集后慢慢溶入10倍体积的缓冲液A里,经过G25尺寸排阻色谱柱购于Sigma)除盐以DEAE Seplite FF(西安蓝晓公司)阴离子交换柱分离后得到初纯化酶液,以上ASK、ASADH、AMT、PPK、PDH、ADH、FDH粗酶以活力比1:2.2:4.5:2.5:4.0:6.0:5.0混合,然后利用LX-1000EP环氧树脂(西安蓝晓公司)进行一次性混合固定,其方法如下:2000-4000U混合酶溶解在1L 25mM pH 8.0的磷酸钾溶液中,随后加入25-65mM苯氧乙酸以及300-500克LX-1000EP环氧树脂至缓冲液,室温搅拌4-8小时后过滤出固定化酶,最后用清水以及25mM pH 8.0磷酸缓冲液各洗涤三次后低温保存待用;固定化混合酶分别具有液体酶的30-70%的活性。
与前述实施例1和实施例2类似,在1L 100mM pH 8.0的三羟甲基氨基甲烷盐酸(Tris.HCl)溶液中先后加入13.3克L-天冬氨酸(100mM),1.1克三磷酸腺苷二钠盐ATP(2mM)、11.4克多聚磷酸(Sigma,25聚,110mM单磷酸)、0.9克氯化镁(10mM)、0.75克氯化钾(10mM)、还原型烟酰胺腺嘌呤二核苷酸磷酸NADPH单钠盐0.76克(1.0mM)、还原型辅酶烟酰胺腺嘌呤二核苷酸NADH二钠盐0.71克(1.0mM)、亚磷酸钠13.5克(110mM)、甲酸氨7.6克(120mM)、丙氨酸0.17克(2mM)、磷酸吡哆醛1.4毫克(0.005mM),待pH值调节到8.0后,2000-4000U固定化混合酶启动反应,反应过程中通过HCl及NaOH水溶液维持pH 6.5-8.5之间,反应液在30℃搅拌5小时后直接过滤固定化酶终止反应,其回收的固定化酶具有40-75%初始活力,过滤的2,4-二氨基丁酸粗溶液通过G25色谱柱除盐,D201阴离子交换树酯除含磷酸杂质,收集的2,4-二氨基丁酸粗品经冻干后用重结晶得白色固体11克(最终收率79%)(活性单位U代表30℃每分钟转化1μM底物所需要的酶量)。
1H-NMR:2.04(m,2.0H),2.65(t,2.0H),3.49(t,1.0H);
13C-NMR:174.7(COOH),52.9(CH),37.5(CH2),28.9(CH2).
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
序列表
<110> 深圳瑞德林生物技术有限公司
<120> 酶催化法制备2,4-二氨基丁酸的工艺
<130> S19P2064
<160> 7
<170> SIPOSequenceListing 1.0
<210> 1
<211> 820
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Met Arg Val Leu Lys Phe Gly Gly Thr Ser Val Ala Asn Ala Glu Arg
1 5 10 15
Phe Leu Arg Val Ala Asp Ile Leu Glu Ser Asn Ala Arg Gln Gly Gln
20 25 30
Val Ala Thr Val Leu Ser Ala Pro Ala Lys Ile Thr Asn His Leu Val
35 40 45
Ala Met Ile Glu Lys Thr Ile Ser Gly Gln Asp Ala Leu Pro Asn Ile
50 55 60
Ser Asp Ala Glu Arg Ile Phe Ala Glu Leu Leu Thr Gly Leu Ala Ala
65 70 75 80
Ala Gln Pro Gly Phe Pro Leu Ala Gln Leu Lys Thr Phe Val Asp Gln
85 90 95
Glu Phe Ala Gln Ile Lys His Val Leu His Gly Ile Ser Leu Leu Gly
100 105 110
Gln Cys Pro Asp Ser Ile Asn Ala Ala Leu Ile Cys Arg Gly Glu Lys
115 120 125
Met Ser Ile Ala Ile Met Ala Gly Val Leu Glu Ala Arg Gly His Asn
130 135 140
Val Thr Val Ile Asp Pro Val Glu Lys Leu Leu Ala Val Gly His Tyr
145 150 155 160
Leu Glu Ser Thr Val Asp Ile Ala Glu Ser Thr Arg Arg Ile Ala Ala
165 170 175
Ser Arg Ile Pro Ala Asp His Met Val Leu Met Ala Gly Phe Thr Ala
180 185 190
Gly Asn Glu Lys Gly Glu Leu Val Val Leu Gly Arg Asn Gly Ser Asp
195 200 205
Tyr Ser Ala Ala Val Leu Ala Ala Cys Leu Arg Ala Asp Cys Cys Glu
210 215 220
Ile Trp Thr Asp Val Asp Gly Val Tyr Thr Cys Asp Pro Arg Gln Val
225 230 235 240
Pro Asp Ala Arg Leu Leu Lys Ser Met Ser Tyr Gln Glu Ala Met Glu
245 250 255
Leu Ser Tyr Phe Gly Ala Lys Val Leu His Pro Arg Thr Ile Thr Pro
260 265 270
Ile Ala Gln Phe Gln Ile Pro Cys Leu Ile Lys Asn Thr Gly Asn Pro
275 280 285
Gln Ala Pro Gly Thr Leu Ile Gly Ala Ser Arg Asp Glu Asp Glu Leu
290 295 300
Pro Val Lys Gly Ile Ser Asn Leu Asn Asn Met Ala Met Phe Ser Val
305 310 315 320
Ser Gly Pro Gly Met Lys Gly Met Val Gly Met Ala Ala Arg Val Phe
325 330 335
Ala Ala Met Ser Arg Ala Arg Ile Ser Val Val Leu Ile Thr Gln Ser
340 345 350
Ser Ser Glu Tyr Ser Ile Ser Phe Cys Val Pro Gln Ser Asp Cys Val
355 360 365
Arg Ala Glu Arg Ala Met Gln Glu Glu Phe Tyr Leu Glu Leu Lys Glu
370 375 380
Gly Leu Leu Glu Pro Leu Ala Val Thr Glu Arg Leu Ala Ile Ile Ser
385 390 395 400
Val Val Gly Asp Gly Met Arg Thr Leu Arg Gly Ile Ser Ala Lys Phe
405 410 415
Phe Ala Ala Leu Ala Arg Ala Asn Ile Asn Ile Val Ala Ile Ala Gln
420 425 430
Gly Ser Ser Glu Arg Ser Ile Ser Val Val Val Asn Asn Asp Asp Ala
435 440 445
Thr Thr Gly Val Arg Val Thr His Gln Met Leu Phe Asn Thr Asp Gln
450 455 460
Val Ile Glu Val Phe Val Ile Gly Val Gly Gly Val Gly Gly Ala Leu
465 470 475 480
Leu Glu Gln Leu Lys Arg Gln Gln Ser Trp Leu Lys Asn Lys His Ile
485 490 495
Asp Leu Arg Val Cys Gly Val Ala Asn Ser Lys Ala Leu Leu Thr Asn
500 505 510
Val His Gly Leu Asn Leu Glu Asn Trp Gln Glu Glu Leu Ala Gln Ala
515 520 525
Lys Glu Pro Phe Asn Leu Gly Arg Leu Ile Arg Leu Val Lys Glu Tyr
530 535 540
His Leu Leu Asn Pro Val Ile Val Asp Cys Thr Ser Ser Gln Ala Val
545 550 555 560
Ala Asp Gln Tyr Ala Asp Phe Leu Arg Glu Gly Phe His Val Val Thr
565 570 575
Pro Asn Lys Lys Ala Asn Thr Ser Ser Met Asp Tyr Tyr His Gln Leu
580 585 590
Arg Tyr Ala Ala Glu Lys Ser Arg Arg Lys Phe Leu Tyr Asp Thr Asn
595 600 605
Val Gly Ala Gly Leu Pro Val Ile Glu Asn Leu Gln Asn Leu Leu Asn
610 615 620
Ala Gly Asp Glu Leu Met Lys Phe Ser Gly Ile Leu Ser Gly Ser Leu
625 630 635 640
Ser Tyr Ile Phe Gly Lys Leu Asp Glu Gly Met Ser Phe Ser Glu Ala
645 650 655
Thr Thr Leu Ala Arg Glu Met Gly Tyr Thr Glu Pro Asp Pro Arg Asp
660 665 670
Asp Leu Ser Gly Met Asp Val Ala Arg Lys Leu Leu Ile Leu Ala Arg
675 680 685
Glu Thr Gly Arg Glu Leu Glu Leu Ala Asp Ile Glu Ile Glu Pro Val
690 695 700
Leu Pro Ala Glu Phe Asn Ala Glu Gly Asp Val Ala Ala Phe Met Ala
705 710 715 720
Asn Leu Ser Gln Leu Asp Asp Leu Phe Ala Ala Arg Val Ala Lys Ala
725 730 735
Arg Asp Glu Gly Lys Val Leu Arg Tyr Val Gly Asn Ile Asp Glu Asp
740 745 750
Gly Val Cys Arg Val Lys Ile Ala Glu Val Asp Gly Asn Asp Pro Leu
755 760 765
Phe Lys Val Lys Asn Gly Glu Asn Ala Leu Ala Phe Tyr Ser His Tyr
770 775 780
Tyr Gln Pro Leu Pro Leu Val Leu Arg Gly Tyr Gly Ala Gly Asn Asp
785 790 795 800
Val Thr Ala Ala Gly Val Phe Ala Asp Leu Leu Arg Thr Leu Ser Trp
805 810 815
Lys Leu Gly Val
820
<210> 2
<211> 367
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Met Lys Asn Val Gly Phe Ile Gly Trp Arg Gly Met Val Gly Ser Val
1 5 10 15
Leu Met Gln Arg Met Val Glu Glu Arg Asp Phe Asp Ala Ile Arg Pro
20 25 30
Val Phe Phe Ser Thr Ser Gln Leu Gly Gln Ala Ala Pro Ser Phe Gly
35 40 45
Gly Thr Thr Gly Thr Leu Gln Asp Ala Phe Asp Leu Glu Ala Leu Lys
50 55 60
Ala Leu Asp Ile Ile Val Thr Cys Gln Gly Gly Asp Tyr Thr Asn Glu
65 70 75 80
Ile Tyr Pro Lys Leu Arg Glu Ser Gly Trp Gln Gly Tyr Trp Ile Asp
85 90 95
Ala Ala Ser Ser Leu Arg Met Lys Asp Asp Ala Ile Ile Ile Leu Asp
100 105 110
Pro Val Asn Gln Asp Val Ile Thr Asp Gly Leu Asn Asn Gly Ile Arg
115 120 125
Thr Phe Val Gly Gly Asn Cys Thr Val Ser Leu Met Leu Met Ser Leu
130 135 140
Gly Gly Leu Phe Ala Asn Asp Leu Val Asp Trp Val Ser Val Ala Thr
145 150 155 160
Tyr Gln Ala Ala Ser Gly Gly Gly Ala Arg His Met Arg Glu Leu Leu
165 170 175
Thr Gln Met Gly His Leu Tyr Gly His Val Ala Asp Glu Leu Ala Thr
180 185 190
Pro Ser Ser Ala Ile Leu Asp Ile Glu Arg Lys Val Thr Thr Leu Thr
195 200 205
Arg Ser Gly Glu Leu Pro Val Asp Asn Phe Gly Val Pro Leu Ala Gly
210 215 220
Ser Leu Ile Pro Trp Ile Asp Lys Gln Leu Asp Asn Gly Gln Ser Arg
225 230 235 240
Glu Glu Trp Lys Gly Gln Ala Glu Thr Asn Lys Ile Leu Asn Thr Ser
245 250 255
Ser Val Ile Pro Val Asp Gly Leu Cys Val Arg Val Gly Ala Leu Arg
260 265 270
Cys His Ser Gln Ala Phe Thr Ile Lys Leu Lys Lys Asp Val Ser Ile
275 280 285
Pro Thr Val Glu Glu Leu Leu Ala Ala His Asn Pro Trp Ala Lys Val
290 295 300
Val Pro Asn Asp Arg Glu Ile Thr Met Arg Glu Leu Thr Pro Ala Ala
305 310 315 320
Val Thr Gly Thr Leu Thr Thr Pro Val Gly Arg Leu Arg Lys Leu Asn
325 330 335
Met Gly Pro Glu Phe Leu Ser Ala Phe Thr Val Gly Asp Gln Leu Leu
340 345 350
Trp Gly Ala Ala Glu Pro Leu Arg Arg Met Leu Arg Gln Leu Ala
355 360 365
<210> 3
<211> 438
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 3
Met Arg Thr Asp Ala Ala Trp Leu Asp Ala His Trp Met Pro Phe Thr
1 5 10 15
Ala Asn Arg Gln Phe Lys Ser Asp Pro Arg Met Ile Val Ser Gly Lys
20 25 30
Gly Ala Tyr Tyr Thr Asp Ala Glu Gly Arg Lys Ile Phe Asp Gly Leu
35 40 45
Ser Gly Leu Trp Cys Thr Gly Leu Gly His Gly Arg Thr Glu Ile Val
50 55 60
Glu Ala Val Ser Arg Gln Val Ala Gln Leu Asp Tyr Ala Pro Ala Phe
65 70 75 80
Gln Phe Gly His Pro Lys Ser Phe Glu Leu Ala Asn Arg Ile Lys Glu
85 90 95
Leu Thr Pro Ala Gly Leu Asp Tyr Val Phe Phe Thr Gly Ser Gly Ser
100 105 110
Glu Ala Ala Asp Thr Ser Leu Lys Met Ala Arg Ala Tyr Trp Arg Ala
115 120 125
Lys Gly Lys Gly Thr Lys Thr Arg Leu Ile Gly Arg Glu Lys Gly Tyr
130 135 140
His Gly Val Asn Phe Gly Gly Ile Ser Val Gly Gly Ile Gly Pro Asn
145 150 155 160
Arg Lys Leu Phe Gly Gln Gly Leu Asp Ala Asp Phe Leu Pro His Thr
165 170 175
Gln Leu Ala Glu Asn Lys Phe Ser Arg Gly Met Pro Glu Arg Gly Ala
180 185 190
Glu Leu Ala Asp Arg Leu Leu Asp Leu Ile Ala Leu His Asp Ala Ser
195 200 205
Asn Ile Ala Ala Val Ile Val Glu Pro Phe Ala Gly Ser Ala Gly Val
210 215 220
Ile Ile Pro Pro Gln Gly Tyr Leu Gln Arg Leu Arg Glu Ile Cys Thr
225 230 235 240
Ala His Asp Ile Leu Leu Ile Phe Asp Glu Val Ile Thr Gly Phe Gly
245 250 255
Arg Ala Gly Ala Met Thr Gly Ala Glu Ala Phe Gly Val Thr Pro Asp
260 265 270
Ile Met Asn Phe Ala Lys Gln Val Thr Asn Gly Val Gln Pro Leu Gly
275 280 285
Gly Val Val Ala Thr Lys Glu Ile Tyr Asp Thr Phe Met Ala Ala Gly
290 295 300
Gly Pro Glu Tyr Met Leu Glu Phe Pro His Gly Tyr Thr Tyr Ser Ala
305 310 315 320
His Pro Val Ala Cys Ala Ala Gly Val Ala Ala Leu Asp Leu Leu Val
325 330 335
Lys Glu Asp Ala Val Ala Arg Val Arg Glu Leu Ala Pro His Phe Glu
340 345 350
Ala Ala Val His Gly Leu Lys Gly Gln Arg His Ile Ala Asp Ile Arg
355 360 365
Asn Tyr Gly Leu Ala Ala Gly Leu Thr Ile Ala Ala Leu Pro Gly Glu
370 375 380
Pro Ala Arg Arg Pro Tyr Glu Ile Ala Met Arg Cys Trp Ala Lys Gly
385 390 395 400
Phe Tyr Val Arg Tyr Gly Gly Asp Thr Ile Gln Leu Ala Pro Pro Phe
405 410 415
Ile Ala Glu Lys Arg Glu Ile Asp Asn Leu Ile Asn Ala Val Ser Asp
420 425 430
Ala Leu Asn Glu Val Asp
435
<210> 4
<211> 286
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Met Pro Met Val Ala Ala Val Glu Phe Ala Lys Ser Pro Ala Glu Val
1 5 10 15
Leu Arg Val Gly Ser Gly Phe Ser Leu Ala Gly Val Asp Pro Glu Ser
20 25 30
Thr Pro Gly Tyr Thr Gly Val Lys Ala Asp Gly Lys Ala Leu Leu Ala
35 40 45
Ala Gln Asp Ala Arg Leu Ala Glu Leu Gln Glu Lys Leu Phe Ala Glu
50 55 60
Gly Lys Phe Gly Asn Pro Lys Arg Leu Leu Leu Ile Leu Gln Ala Met
65 70 75 80
Asp Thr Ala Gly Lys Gly Gly Ile Val Ser His Val Val Gly Ala Met
85 90 95
Asp Pro Gln Gly Val Gln Leu Thr Ala Phe Lys Ala Pro Thr Asp Glu
100 105 110
Glu Lys Ser His Asp Phe Leu Trp Arg Ile Glu Lys Gln Val Pro Ala
115 120 125
Ala Gly Met Val Gly Val Phe Asp Arg Ser Gln Tyr Glu Asp Val Leu
130 135 140
Ile His Arg Val His Gly Trp Ala Asp Ala Ala Glu Leu Glu Arg Arg
145 150 155 160
Tyr Ala Ala Ile Asn Asp Phe Glu Ser Arg Leu Thr Glu Gln Gly Thr
165 170 175
Thr Ile Val Lys Val Met Leu Asn Ile Ser Lys Asp Glu Gln Lys Lys
180 185 190
Arg Leu Ile Ala Arg Leu Asp Asp Pro Ser Lys His Trp Lys Tyr Ser
195 200 205
Arg Gly Asp Leu Ala Glu Arg Ala Tyr Trp Asp Asp Tyr Met Asp Ala
210 215 220
Tyr Ser Val Ala Phe Glu Lys Thr Ser Thr Glu Ile Ala Pro Trp His
225 230 235 240
Val Val Pro Ala Asn Lys Lys Trp Tyr Ala Arg Ile Ala Val Gln Gln
245 250 255
Leu Leu Leu Asp Ala Leu Gly Gly Leu Gln Leu Asp Trp Pro Lys Ala
260 265 270
Asp Phe Asp Val Ala Ala Glu Arg Ala Leu Val Val Glu Ser
275 280 285
<210> 5
<211> 336
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 5
Met Leu Pro Lys Leu Val Ile Thr His Arg Val His Asp Glu Ile Leu
1 5 10 15
Gln Leu Leu Ala Pro His Cys Glu Leu Met Thr Asn Gln Thr Asp Ser
20 25 30
Thr Leu Thr Arg Glu Glu Ile Leu Arg Arg Cys Arg Asp Ala Gln Ala
35 40 45
Met Met Ala Phe Met Pro Asp Arg Val Asp Ala Asp Phe Leu Gln Ala
50 55 60
Cys Pro Glu Leu Arg Val Val Gly Cys Ala Leu Lys Gly Phe Asp Asn
65 70 75 80
Phe Asp Val Asp Ala Cys Thr Ala Arg Gly Val Trp Leu Thr Phe Val
85 90 95
Pro Asp Leu Leu Thr Val Pro Thr Ala Glu Leu Ala Ile Gly Leu Ala
100 105 110
Val Gly Leu Gly Arg His Leu Arg Ala Ala Asp Ala Phe Val Arg Ser
115 120 125
Gly Glu Phe Gln Gly Trp Gln Pro Gln Phe Tyr Gly Thr Gly Leu Asp
130 135 140
Asn Ala Thr Val Gly Ile Leu Gly Met Gly Ala Ile Gly Leu Ala Met
145 150 155 160
Ala Asp Arg Leu Gln Gly Trp Gly Ala Thr Leu Gln Tyr His Glu Ala
165 170 175
Lys Ala Leu Asp Thr Gln Thr Glu Gln Arg Leu Gly Leu Arg Gln Val
180 185 190
Ala Cys Ser Glu Leu Phe Ala Ser Ser Asp Phe Ile Leu Leu Ala Leu
195 200 205
Pro Leu Asn Ala Asp Thr Gln His Leu Val Asn Ala Glu Leu Leu Ala
210 215 220
Leu Val Arg Pro Gly Ala Leu Leu Val Asn Pro Cys Arg Gly Ser Val
225 230 235 240
Val Asp Glu Ala Ala Val Leu Ala Ala Leu Glu Arg Gly Gln Leu Gly
245 250 255
Gly Tyr Ala Ala Asp Val Phe Glu Met Glu Asp Trp Ala Arg Ala Asp
260 265 270
Arg Pro Arg Leu Ile Asp Pro Ala Leu Leu Ala His Pro Asn Thr Leu
275 280 285
Phe Thr Pro His Ile Gly Ser Ala Val Arg Ala Val Arg Leu Glu Ile
290 295 300
Glu Arg Cys Ala Ala Gln Asn Ile Ile Gln Val Leu Ala Gly Ala Arg
305 310 315 320
Pro Ile Asn Ala Ala Asn Arg Leu Pro Lys Ala Glu Pro Ala Ala Cys
325 330 335
<210> 6
<211> 371
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 6
Met Leu Val Gly Ile Pro Thr Glu Ile Lys Asn Asn Glu Tyr Arg Val
1 5 10 15
Ala Ile Thr Pro Ala Gly Val Ala Glu Leu Thr Arg Arg Gly His Glu
20 25 30
Val Ile Ile Gln Ala Gly Ala Gly Glu Gly Ser Ala Ile Ser Asp Arg
35 40 45
Asp Phe Lys Ala Ala Gly Ala Glu Ile Val Asn Thr Ala Asp Gln Val
50 55 60
Trp Ser Glu Ala Glu Leu Leu Leu Lys Val Lys Glu Pro Ile Glu Pro
65 70 75 80
Glu Tyr Ser Arg Met Arg Lys Gly Gln Thr Leu Phe Thr Tyr Leu His
85 90 95
Leu Ala Ala Ser Lys Pro Cys Thr Asp Ala Leu Leu Ala Ser Gly Thr
100 105 110
Thr Ser Ile Ala Tyr Glu Thr Val Gln Thr Ala Glu Gly Ala Leu Pro
115 120 125
Leu Leu Ala Pro Met Ser Glu Val Ala Gly Arg Leu Ser Ala Gln Val
130 135 140
Gly Ala Tyr His Leu Met Arg Ser Tyr Gly Gly Arg Gly Val Leu Met
145 150 155 160
Gly Gly Val Pro Gly Val Ala Pro Ala Glu Val Val Val Ile Gly Ala
165 170 175
Gly Thr Ala Gly Tyr Asn Ala Ala Arg Val Ala Ala Gly Met Gly Ala
180 185 190
His Val Thr Val Phe Asp Leu Asn Ile Asn Thr Leu Arg Arg Val Asp
195 200 205
Gly Glu Phe Gly Gly Arg Ile Glu Thr Arg Tyr Ser Ser Ser Leu Glu
210 215 220
Leu Glu Glu Ala Val Lys Lys Ala Asp Leu Val Ile Gly Ala Val Leu
225 230 235 240
Val Pro Gly Ala Lys Ala Pro Lys Leu Val Thr Asn Ser Thr Val Ala
245 250 255
His Met Lys Pro Gly Ala Val Leu Val Asp Ile Ala Ile Asp Gln Gly
260 265 270
Gly Cys Phe Glu Asp Ser Arg Pro Thr Thr His Asp Glu Pro Thr Phe
275 280 285
Lys Val His Asp Thr Ile Phe Tyr Cys Val Ala Asn Met Pro Gly Ala
290 295 300
Val Pro Arg Thr Ser Thr Phe Ala Leu Thr Asn Ser Thr Met Pro Tyr
305 310 315 320
Val Leu Lys Leu Ala Asp Lys Gly Trp Gln Ala Ala Cys Ala Ser Asp
325 330 335
Ser Ala Leu Ala Lys Gly Leu Ser Thr His Asp Gly Lys Leu Leu Ser
340 345 350
Glu Ala Val Ala Lys Asp Leu Asp Leu Pro Phe Thr Asp Ala Ala Gln
355 360 365
Phe Leu Ala
370
<210> 7
<211> 715
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 7
Met Lys Lys Val Val Thr Val Cys Pro Tyr Cys Ala Ser Gly Cys Lys
1 5 10 15
Ile Asn Leu Val Val Asp Asn Gly Lys Ile Val Arg Ala Glu Ala Ala
20 25 30
Gln Gly Lys Thr Asn Gln Gly Thr Leu Cys Leu Lys Gly Tyr Tyr Gly
35 40 45
Trp Asp Phe Ile Asn Asp Thr Gln Ile Leu Thr Pro Arg Leu Lys Thr
50 55 60
Pro Met Ile Arg Arg Gln Arg Gly Gly Lys Leu Glu Pro Val Ser Trp
65 70 75 80
Asp Glu Ala Leu Asn Tyr Val Ala Glu Arg Leu Ser Ala Ile Lys Glu
85 90 95
Lys Tyr Gly Pro Asp Ala Ile Gln Thr Thr Gly Ser Ser Arg Gly Thr
100 105 110
Gly Asn Glu Thr Asn Tyr Val Met Gln Lys Phe Ala Arg Ala Val Ile
115 120 125
Gly Thr Asn Asn Val Asp Cys Cys Ala Arg Val Ser His Gly Pro Ser
130 135 140
Val Ala Gly Leu His Gln Ser Val Gly Asn Gly Ala Met Ser Asn Ala
145 150 155 160
Ile Asn Glu Ile Asp Asn Thr Asp Leu Val Phe Val Phe Gly Tyr Asn
165 170 175
Pro Ala Asp Ser His Pro Ile Val Ala Asn His Val Ile Asn Ala Lys
180 185 190
Arg Asn Gly Ala Lys Ile Ile Val Cys Asp Pro Arg Lys Ile Glu Thr
195 200 205
Ala Arg Ile Ala Asp Met His Ile Ala Leu Lys Asn Gly Ser Asn Ile
210 215 220
Ala Leu Leu Asn Ala Met Gly His Val Ile Ile Glu Glu Asn Leu Tyr
225 230 235 240
Asp Lys Ala Phe Val Ala Ser Arg Thr Glu Gly Phe Glu Glu Tyr Arg
245 250 255
Lys Ile Val Glu Gly Tyr Thr Pro Glu Ser Val Glu Asp Ile Thr Gly
260 265 270
Val Ser Ala Ser Glu Ile Arg Gln Ala Ala Arg Met Tyr Ala Gln Ala
275 280 285
Lys Ser Ala Ala Ile Leu Trp Gly Met Gly Val Thr Gln Phe Tyr Gln
290 295 300
Gly Val Glu Thr Val Arg Ser Leu Thr Ser Leu Ala Met Leu Thr Gly
305 310 315 320
Asn Leu Gly Lys Pro His Ala Gly Val Asn Pro Val Arg Gly Gln Asn
325 330 335
Asn Val Gln Gly Ala Cys Asp Met Gly Ala Leu Pro Asp Thr Tyr Pro
340 345 350
Gly Tyr Gln Tyr Val Lys Asp Pro Ala Asn Arg Glu Lys Phe Ala Lys
355 360 365
Ala Trp Gly Val Glu Ser Leu Pro Ala His Thr Gly Tyr Arg Ile Ser
370 375 380
Glu Leu Pro His Arg Ala Ala His Gly Glu Val Arg Ala Ala Tyr Ile
385 390 395 400
Met Gly Glu Asp Pro Leu Gln Thr Asp Ala Glu Leu Ser Ala Val Arg
405 410 415
Lys Ala Phe Glu Asp Leu Glu Leu Val Ile Val Gln Asp Ile Phe Met
420 425 430
Thr Lys Thr Ala Ser Ala Ala Asp Val Ile Leu Pro Ser Thr Ser Trp
435 440 445
Gly Glu His Glu Gly Val Phe Thr Ala Ala Asp Arg Gly Phe Gln Arg
450 455 460
Phe Phe Lys Ala Val Glu Pro Lys Trp Asp Leu Lys Thr Asp Trp Gln
465 470 475 480
Ile Ile Ser Glu Ile Ala Thr Arg Met Gly Tyr Pro Met His Tyr Asn
485 490 495
Asn Thr Gln Glu Ile Trp Asp Glu Leu Arg His Leu Cys Pro Asp Phe
500 505 510
Tyr Gly Ala Thr Tyr Glu Lys Met Gly Glu Leu Gly Phe Ile Gln Trp
515 520 525
Pro Cys Arg Asp Thr Ser Asp Ala Asp Gln Gly Thr Ser Tyr Leu Phe
530 535 540
Lys Glu Lys Phe Asp Thr Pro Asn Gly Leu Ala Gln Phe Phe Thr Cys
545 550 555 560
Asp Trp Val Ala Pro Ile Asp Lys Leu Thr Asp Glu Tyr Pro Met Val
565 570 575
Leu Ser Thr Val Arg Glu Val Gly His Tyr Ser Cys Arg Ser Met Thr
580 585 590
Gly Asn Cys Ala Ala Leu Ala Ala Leu Ala Asp Glu Pro Gly Tyr Ala
595 600 605
Gln Ile Asn Thr Glu Asp Ala Lys Arg Leu Gly Ile Glu Asp Glu Ala
610 615 620
Leu Val Trp Val His Ser Arg Lys Gly Lys Ile Ile Thr Arg Ala Gln
625 630 635 640
Val Ser Asp Arg Pro Asn Lys Gly Ala Ile Tyr Met Thr Tyr Gln Trp
645 650 655
Trp Ile Gly Ala Cys Asn Glu Leu Val Thr Glu Asn Leu Ser Pro Ile
660 665 670
Thr Lys Thr Pro Glu Tyr Lys Tyr Cys Ala Val Arg Val Glu Pro Ile
675 680 685
Ala Asp Gln Arg Ala Ala Glu Gln Tyr Val Ile Asp Glu Tyr Asn Lys
690 695 700
Leu Lys Thr Arg Leu Arg Glu Ala Ala Leu Ala
705 710 715

Claims (1)

1.一种酶催化法制备2,4-二氨基丁酸的工艺,其特征在于,反应原料L-天冬氨酸、ATP或其盐、磷酸吡哆醛、丙氨酸、NADPH或其盐在pH值6.0-9.0的反应介质中,与天冬氨酸激酶ASK、天冬氨酸半醛氧化酶ASADH及转氨酶AMT进行酶催化反应,生成2,4-二氨基丁酸;所述天冬氨酸激酶ASK、天冬氨酸半醛氧化酶ASADH及转氨酶AMT的序列依次如SEQ ID NO.1-3所示;
同时还包括:向反应原料中添加多聚磷酸、亚磷酸或其盐、甲酸铵、氯化镁、氯化钾、NADH或其盐,以及添加ATP再生酶PPK、NADP再生酶PDH、丙氨酸脱氢酶ADH以及甲酸脱氢酶FDH进行酶催化反应;所述ATP再生酶PPK、NADP再生酶PDH、丙氨酸脱氢酶ADH以及甲酸脱氢酶FDH的序列依次如SEQ ID NO.4-7所示;
所述各酶以表达各酶的宿主细胞、各酶的酶液或各酶的固定化酶形式参与酶催化反应;
所述表达各酶的宿主细胞为含有表达各酶的载体的大肠杆菌;
所述各酶的酶液为从表达各酶的宿主细胞中提取的酶液;
还包括2,4-二氨基丁酸的纯化步骤:
过色谱柱除盐,然后阴离子交换树酯除去溶液中磷酸化合物,最后收集的2,4-二氨基丁酸粗品经冻干后重结晶;
所述反应介质为Tris.HCl。
CN201911229933.7A 2019-12-04 2019-12-04 酶催化法制备2,4-二氨基丁酸的工艺 Active CN110804634B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911229933.7A CN110804634B (zh) 2019-12-04 2019-12-04 酶催化法制备2,4-二氨基丁酸的工艺

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911229933.7A CN110804634B (zh) 2019-12-04 2019-12-04 酶催化法制备2,4-二氨基丁酸的工艺

Publications (2)

Publication Number Publication Date
CN110804634A CN110804634A (zh) 2020-02-18
CN110804634B true CN110804634B (zh) 2022-02-25

Family

ID=69492436

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911229933.7A Active CN110804634B (zh) 2019-12-04 2019-12-04 酶催化法制备2,4-二氨基丁酸的工艺

Country Status (1)

Country Link
CN (1) CN110804634B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111979206B (zh) * 2019-05-24 2021-08-17 深圳瑞德林生物技术有限公司 固定化融合酶及用其制备谷胱甘肽的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102181412A (zh) * 2011-03-09 2011-09-14 南京工业大学 一种二氨基丁酸-2-酮戊二酸转氨酶及其应用
CN106574237A (zh) * 2014-06-05 2017-04-19 Cj第制糖株式会社 生产o‑乙酰高丝氨酸的微生物和使用其生产o‑乙酰高丝氨酸的方法
CN108138191A (zh) * 2015-08-27 2018-06-08 Cj第制糖株式会社 具有l-赖氨酸生产能力的棒状杆菌属微生物及利用其生产l-赖氨酸的方法
WO2019136585A1 (en) * 2018-01-09 2019-07-18 Cathay R & D Center Co., Ltd. Regulation of csr system for production of lysine and lysine-derived products

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105861598A (zh) * 2016-04-27 2016-08-17 深圳市古特新生生物科技有限公司 一种酶法再生atp的方法及其应用
JP6964314B2 (ja) * 2017-05-12 2021-11-10 三井化学株式会社 組換え微生物、組換え微生物を用いたピリドキサミン又はその塩の製造方法、及び組換え微生物を用いたピリドキサール又はその塩の製造方法
CN109280680B (zh) * 2017-07-21 2023-01-10 北京天开易达生物科技有限公司 一种酶促联产的方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102181412A (zh) * 2011-03-09 2011-09-14 南京工业大学 一种二氨基丁酸-2-酮戊二酸转氨酶及其应用
CN106574237A (zh) * 2014-06-05 2017-04-19 Cj第制糖株式会社 生产o‑乙酰高丝氨酸的微生物和使用其生产o‑乙酰高丝氨酸的方法
CN108138191A (zh) * 2015-08-27 2018-06-08 Cj第制糖株式会社 具有l-赖氨酸生产能力的棒状杆菌属微生物及利用其生产l-赖氨酸的方法
WO2019136585A1 (en) * 2018-01-09 2019-07-18 Cathay R & D Center Co., Ltd. Regulation of csr system for production of lysine and lysine-derived products

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
林生山薰豆幼苗2,4-二氨基丁酸的合成及其与胁迫条件的关系;沈黎明等;《植物资源与环境》;19961231;第5卷(第2期);15-18 *
林生山黛豆中2,-4二氨基丁酸合成代谢的体外酶学研究;穆小民等;《植物学报》;19971231;第39卷(第6期);537-540 *

Also Published As

Publication number Publication date
CN110804634A (zh) 2020-02-18

Similar Documents

Publication Publication Date Title
CN109750009B (zh) 一种草铵膦脱氢酶突变体及其应用
CN112795606B (zh) 一种β-烟酰胺单核苷酸的酶催化合成方法
JPS63233798A (ja) 5′−グアニル酸の製造法
CN110777123A (zh) 突变的l-氨基酸连接酶以及酶催化法制备l-谷氨酸-l-色氨酸二肽的工艺
CN113621590B (zh) 一种s-尼古丁的制备方法
CN110804634B (zh) 酶催化法制备2,4-二氨基丁酸的工艺
CN112980906B (zh) 一种用于制备β-烟酰胺单核苷酸的酶组合物及其应用
CN109679978B (zh) 一种用于制备l-2-氨基丁酸的重组共表达体系及其应用
CN114854659B (zh) 一种麦角硫因生产工艺及其应用
CN109722442B (zh) 7β-羟基胆酸脱氢酶及其应用
CN112175892B (zh) 一种共表达l-苏氨酸醛缩酶与plp合酶的工程菌及应用
WO2019123166A1 (en) Nucleotide sequences encoding 3-quinuclidinone reductase and glucose dehydrogenase and soluble expression thereof
CN116855467A (zh) 一种化学-酶偶联方法用于合成麦角硫因
CN112921012B (zh) 谷氨酸棒杆菌meso-2,6-二氨基庚二酸脱氢酶突变体及其应用
CN110713967B (zh) 一种转化合成左旋多巴效率提高的大肠杆菌及其应用
CN112779233A (zh) 重组草铵膦脱氢酶、基因工程菌及其在制备l-草铵膦中的应用
CN113881730B (zh) L-半乳糖的合成方法
CN113528475B (zh) 一种羰基还原酶突变体及其在制备甾体激素--睾酮中的应用
CN113881728B (zh) 7-氨甲基-7-脱氮鸟嘌呤(PreQ1)的制备方法
CN114875087B (zh) 以β-吲哚基丙氨酸为底物合成5-羟基β-吲哚基丙氨酸的方法及其应用
CN114480315B (zh) 一种Baeyer-Villiger单加氧酶及其在布立西坦合成中的应用
CN114574454B (zh) 一种短链脱氢酶及其突变体和应用
CN117757865A (zh) 一种多酶偶联转化制备l-半胱氨酸的方法
CN117384986A (zh) 一种生物酶法催化合成假尿苷的方法
CN113481121A (zh) 一种双菌生物催化剂及在合成西他列汀中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP02 Change in the address of a patent holder

Address after: 518000 floor 3, building 2, Shenzhen biological incubation base, No. 10, Gaoxin Zhongyi Road, Maling community, Yuehai street, Nanshan District, Shenzhen, Guangdong

Patentee after: SHENZHEN READLINE BIOTECHNOLOGY Co.,Ltd.

Address before: 518057 Room 101, 1st floor, building 2, Shenzhen biological incubation base, No.10, Gaoxin middle 1st Road, Maling community, Yuehai street, Nanshan District, Shenzhen City, Guangdong Province

Patentee before: SHENZHEN READLINE BIOTECHNOLOGY Co.,Ltd.

CP02 Change in the address of a patent holder
TR01 Transfer of patent right

Effective date of registration: 20240418

Address after: 518000 floor 3, building 2, Shenzhen biological incubation base, No. 10, Gaoxin Zhongyi Road, Maling community, Yuehai street, Nanshan District, Shenzhen, Guangdong

Patentee after: SHENZHEN READLINE BIOTECHNOLOGY Co.,Ltd.

Country or region after: China

Patentee after: Gansu ruidilin biological Co.,Ltd.

Address before: 518000 floor 3, building 2, Shenzhen biological incubation base, No. 10, Gaoxin Zhongyi Road, Maling community, Yuehai street, Nanshan District, Shenzhen, Guangdong

Patentee before: SHENZHEN READLINE BIOTECHNOLOGY Co.,Ltd.

Country or region before: China

TR01 Transfer of patent right